ESTRO 2025 - Abstract Book

S965

Clinical – Head & neck

ESTRO 2025

References:

Ward MC et al. Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative. Int J Radiat Oncol Biol Phys 2018. https://doi.org/10.1016/j.ijrobp.2017.06.012. Zhao X et al. Deep learning signatures reveal multiscale intratumor heterogeneity associated with biological functions and survival in recurrent nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 2022. https://doi.org/10.1007/s00259-022-05793-x. Beddok A al. [18F]-FDG PET and MRI radiomic signatures to predict the risk and the location of tumor recurrence after reirradiation in head and neck cancer. Eur J Nucl Med Mol Imaging 2023. https://doi.org/10.1007/s00259-022 06000-7.

1251

Mini-Oral Adaptive dose painting by numbers for head and neck cancer: long term analysis of a randomized trial. Fréderic Duprez 1,2 , Stéphanie Deheneffe 3 , Jean-François Daisne 4,5 , Sarah Deschuymer 1 , Aurélie De Bruycker 6 , Indira Madani 7 , Werner De Gersem 1,2 , Tom Vercauteren 1 , Wilfried De Neve 2 1 Radiation Oncology, Ghent University Hospital, Ghent, Belgium. 2 Human Structures and Repair, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium. 3 Radiation Oncology, CHU-UCL Namur, Namur, Belgium. 4 Radiation Oncology, University Hospital Leuven, Leuven, Belgium. 5 Department of Oncology, Leuven Cancer Institute (LKI), Catholic University of Leuven, Leuven, Belgium. 6 Radiation Oncology, AZ Groeninge, Kortrijk, Belgium. 7 Radiation Oncology, University Hospital of Zürich, Zürich, Switzerland Purpose/Objective: We previously published clinical results of a multi-centre randomized controlled phase II trial comparing standard IMRT (S-IMRT) to 3-phase adaptive dose-painting-by-numbers (A-DPBN) for head and neck cancer (HNC) 1 with median follow-up 37 months (living patients). This study resulted in better 2-year local control (LC) in A-DPBN (88% vs. 75%, p=0.021) 1 . More patients in A-DPBN had late grade≥3 mucosal ulcers (33% vs. 7%, p =0.003) correlating with continuation of smoking after therapy. 1 We report long-term outcomes beyond 3 years after treatment. Material/Methods: Between 2011-2015, 95 HNC patients were randomized between S-IMRT (n=48) and A-DPBN (n=47). Patient characteristics and dose prescription protocols are shown in Figure 1.